The COMPASSHER2 Trials COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer: COMPASSHER2 Residual Disease RD, a Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

Brief Summary

Type:
Breast Cancer

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT04457596

Study #:
STUDY00147128

Start Date:
Jul 21, 2021

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04457596

View Complete Trial Details & Eligibility at ClinicalTrials.gov